Key Stats for Illumina Stock
- 52-Week Range: $88.00 to $226.84
- Current Price: $224.91
- Street Mean Target: ~$199
- Street High Target: $230
- NTM P/E (TIKR): ~39x
- YTD Return: +68%
Illumina stock’s run has outpaced even a Street that keeps raising its numbers. Analyze ILMN on TIKR for free →
Illumina’s Clinical Business Is Finally Doing the Heavy Lifting
Illumina (ILMN) makes the machines and reagents that allow scientists and clinicians to read DNA at scale. Its flagship NovaSeq X sequencer sits inside hospitals, pharmaceutical companies, and research labs around the world, and the consumables those customers purchase on every run, the cartridges, flow cells, and chemistry kits, are where the real recurring revenue lives.
After years of distraction from its ill-fated acquisition of cancer-detection company GRAIL, Illumina divested that business and re-emerged in 2025 as a leaner, more focused operation. The market has rewarded the reset in a big way.
Second-quarter revenue came in at $1.16 billion, up 9.5% year over year, marking the fastest growth rate since CEO Jacob Thaysen joined the company.
Clinical markets, representing roughly 65% of sequencing consumables revenue, were the primary driver, with clinical consumables growing around 15% outside of China, and U.S. and Canadian clinical growth coming in above 20%.
Instrument revenue also surprised to the upside. Sequencing instrument revenue rose 31% year over year, with over 95 NovaSeq X placements during the quarter alone. StockStory + 2
Full-year 2026 revenue guidance was raised to $4.60 billion to $4.64 billion, with adjusted EPS guidance lifted to $5.30 to $5.40. Research markets remain the soft spot, as funding uncertainty has kept academic and government lab spending subdued, and the company does not expect a meaningful recovery there for the rest of the year.
Clinical demand has been strong enough to carry the story, though, and shares have more than doubled from their 52-week low of $88 as investors have taken notice.
See analysts’ growth forecasts and price targets for Illumina stock (It’s free) >>>
Why the Installed Base Is the Number That Actually Matters
Illumina’s business model follows a logic investors will recognize from other hardware platforms: sell the instrument, then earn high-margin recurring revenue from the consumables every customer needs to run it.
Each NovaSeq X placement today is a future consumables revenue stream, and the durability of that stream depends on what customers are using the machine for.
Clinical applications, things like cancer genomics, rare disease diagnosis, and newborn screening, tend to require consistent, high-volume sequencing over many years. Research projects are more episodic, so as the mix shifts toward clinical, Illumina’s revenue base becomes meaningfully stickier.
Approximately 83% of sequencing volumes and 59% of sequencing revenue had already transitioned to NovaSeq X as of the second quarter. Each migration from an older platform locks a customer into higher-throughput capacity designed for clinical-scale demand.
Beyond the core instrument cycle, Illumina is also investing in spatial biology, proteomics, and its Billion Cell Atlas initiative, which are earlier-stage bets on multi-omics workflows that could expand the addressable market considerably over the next several years. Investing.com
The gross margin chart tells an important part of the story here. Margins peaked above 71% in 2022 before compressing to around 65% in 2023, weighed down by the costs and distractions associated with the GRAIL saga.
Since the divestiture, margins have recovered to roughly 68%, and the Q2 non-GAAP gross margin of 68.2% came in slightly above expectations, even with higher freight and memory costs during the quarter.
Operating margin reached around 22% in Q2, and free cash flow for the quarter was $162 million, reflecting a company that has successfully rebuilt its cost discipline after a difficult few years.
See how Illumina performs against its peers in TIKR (It’s free!) >>>
What Wall Street Actually Thinks About ILMN Right Now
Here is where the story gets more complicated. The fundamental recovery is genuine, but the stock’s rally has outrun the consensus view of what it’s worth.
At around $225, Illumina now trades above its 52-week high and above the Street’s mean price target, so understanding where analysts stand helps frame the risk investors are accepting at current prices.
The Street mean target sits at around $199, implying the stock currently trades roughly 13% above where the average analyst sees fair value. The high target of $230 offers only a narrow band of upside from here, and the analyst mix leans cautious, with 6 buys, 4 outperforms, 6 holds, and 4 underperforms or sells out of 19 estimates.
Some analysts view the stock as meaningfully overvalued at current levels, with fair value estimates running well below where shares trade today.
The forward P/E of roughly 39 times reflects optimism about the clinical sequencing growth trajectory, but also leaves little cushion if the research market recovery takes longer than expected or if competitive pricing pressure from rivals like Roche weighs on margins.
Should You Buy Illumina Stock?
Illumina is a genuinely better business today than it was two years ago. The clinical momentum is real, the balance sheet has improved, and the installed base is growing in the right direction, but at around $225 per share, most of that good news appears already priced in.
The stock sits above the Street mean target, trades at a premium multiple, and still carries a soft research market as a drag on near-term results. Investors who believe the clinical ramp accelerates further and the research recovery arrives sooner than expected may find the setup reasonable, but buying here means paying for optimism rather than any meaningful margin of safety.
See analysts’ growth forecasts and price targets for Illumina stock (It’s free!) >>>
Looking for New Opportunities?
- See which stocks billionaire investors are buying to follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
